Mixue Xie
Overview
Explore the profile of Mixue Xie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma J, Sun S, Xie Y, Zhou S, Wu M, Zuo X, et al.
Blood Cancer J
. 2025 Feb;
15(1):19.
PMID: 39948069
No abstract available.
2.
Li S, Zhang R, Gong K, Xie M, Ma W, Gao G
IEEE Trans Neural Netw Learn Syst
. 2023 Dec;
36(2):2538-2550.
PMID: 38127604
Active domain adaptation (ADA), which enormously improves the performance of unsupervised domain adaptation (UDA) at the expense of annotating limited target data, has attracted a surge of interest. However, in...
3.
Ge C, Huang R, Xie M, Lai Z, Song S, Li S, et al.
IEEE Trans Neural Netw Learn Syst
. 2023 Nov;
36(1):1160-1170.
PMID: 37943650
Unsupervised domain adaptation (UDA) aims to adapt models learned from a well-annotated source domain to a target domain, where only unlabeled samples are given. Current UDA approaches learn domain-invariant features...
4.
Xie M, Lu Y, Ouyang G, Li X, Shi T, Yang M, et al.
Br J Haematol
. 2023 Jul;
202(6):1119-1126.
PMID: 37434414
To reducing chemotherapy-related toxicity, the chemo-free regimens become a new trend of Ph + ALL treatment. Therefore, we conducted a phase 2 trial of dasatinib plus prednisone, as induction (Course...
5.
Xie M, Shi T, Jiang Q, Jia Y, Zhou D, Tong H, et al.
Cancer
. 2023 Mar;
129(10):1523-1536.
PMID: 36882308
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) as postremission treatment is recommended for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) in current guidelines. However, comparisons of later generation tyrosine kinase inhibitors...
6.
Zhou D, Huang X, Xie M, Zhu L, Huang X, Li X, et al.
Am J Hematol
. 2023 Feb;
98(5):E106-E109.
PMID: 36789563
No abstract available.
7.
Jiang Q, Xie M, Chen R, Yan F, Ye C, Li Q, et al.
Front Immunol
. 2022 Sep;
13:973601.
PMID: 36105816
Background: As the forefront of nanomedicine, bionic nanotechnology has been widely used for drug delivery in order to obtain better efficacy but less toxicity for cancer treatments. With the rise...
8.
Zhu L, Chen R, Li X, Xie M, Yang X, Sun J, et al.
Hematology
. 2022 Apr;
27(1):420-425.
PMID: 35413219
Background: Acute myeloid leukemia (AML) with t(8;21) is generally associated with a favorable clinical course. Loss of sex chromosome (LOS) are frequently observed in t (8;21) AML, but the prognostic...
9.
Shi T, Xie M, Chen L, Yuan W, Wang Y, Huang X, et al.
Exp Hematol Oncol
. 2022 Mar;
11(1):13.
PMID: 35277197
Background: The differential signaling and outcome of patients with p190 or p210 transcripts of BCR-ABL1 have been systematically investigated in chronic myeloid leukemia rather than in Philadelphia chromosome-positive acute lymphoblastic...
10.
Lei W, Xie M, Jiang Q, Xu N, Li P, Liang A, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359816
Chimeric antigen receptors T (CAR-T) cell therapy of cancer is a rapidly evolving field. It has been shown to be remarkably effective in cases of hematological malignancies, and its approval...